<DOC>
	<DOCNO>NCT02698384</DOCNO>
	<brief_summary>The study aim evaluate biochemical clinical effectiveness symptom tumor size monotherapy Lanreotide 120mg acromegalic subject , describe criterion start alternative strategy , describe modality global effectiveness alternative strategy .</brief_summary>
	<brief_title>Therapeutic Strategies Acromegalic Subjects Treated With Lanreotide 120mg</brief_title>
	<detailed_description />
	<mesh_term>Acromegaly</mesh_term>
	<mesh_term>Lanreotide</mesh_term>
	<mesh_term>Angiopeptin</mesh_term>
	<criteria>Male female age 18 year , suffer acromegaly Treatment na√Øve treat subject ( whatever previous treatment except Lanreotide 120mg radiotherapy ) achieve biochemical control physician 's opinion . Requiring treatment Somatostatin analog ( SSA ) Having perform Magnetic Resonance Imaging ( MRI ) evaluate tumor size within previous 12 week ( postsurgery MRI operate subject ) In physician already decided initiate treatment Lanreotide 120mg monotherapy Subject previously/currently treat Lanreotide 120mg History radiotherapy acromegaly Subject require surgical intervention relief sign symptom associate tumor compression Concomitant prolactin hypersecretion require treatment dopaminergic agonist Active neoplastic disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>